GeneralConnection.com ➔ Dictionary
Dictionary Search

polycythemia

Synonyms

Noun

1. blood disease

2. blood disorder

Usage
FDA Approves BESREMi Pen for Self-Administration in Polycythemia Vera - Oncology Nursing News
Polycythemia Vera: JAK2 Inhibitor Patient Selection - Targeted Oncology
FDA Approves Prefilled Pen for Ropeginterferon Alfa-2b in Polycythemia Vera - OncLive
Polycythemia Vera Prevalence to Near 100K by 2030 as Symptom Burden Grows - AJMC
Optimized post-GWAS analysis identifies therapeutic targets for essential thrombocythemia and polycythemia vera - Nature
PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen™ (ropeginterferon alfa-2b-njft) for Polycythemia Vera - Business Wire
Emerging Evidence for Earlier Intervention in Low-Risk Polycythemia Vera - Targeted Oncology
Potential Rusfertide Approval May Offer More Control of Polycythemia Vera - CancerNetwork
FDA Grants Priority Review to Rusfertide for Polycythemia Vera - Cure Today
Hepcidin Modulation in Polycythemia Vera: Current Landscape and Next Steps - ASCO Daily News
Hepcidin Mimetic Rusfertide Gets Priority Review for Polycythemia Vera - Hematology Advisor
FDA approves BESREMi Pen for polycythemia vera treatment - Investing.com
GLP-1a Therapy Improves Survival in Patients with Polycythemia Vera and Myelodysplastic Syndromes - Cleveland Clinic
LLM Tool Significantly Reduces Participant Screening Burdens, Improves Enrollment for Phase III Trial in Polycythemia Vera - The ASCO Post
Revisiting old drugs and drug combinations for polycythemia vera and related neoplasms - Frontiers
Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera - Nature
Rusfertide Earns FDA Priority Review in Polycythemia Vera - CancerNetwork
Optimizing Treatment Outcomes in Polycythemia Vera - Targeted Oncology
Considerations in the First-Line Setting in Polycythemia Vera - Targeted Oncology
Navigating Resistance and Intolerance in High-Risk Polycythemia Vera - Targeted Oncology
Phase 2 Trial Begins for First-in-Class Polycythemia Vera Treatment - Docwire News
Rusfertide Maintains Hematocrit Control in Patients With Polycythemia Vera - Cure Today
Rusfertide May Become Part of Polycythemia Vera Armamentarium - CancerNetwork
What Fatigue Feels Like for a Patient With Polycythemia Vera - Cure Today
Developers Submit NDA to FDA for Rusfertide in Polycythemia Vera - CancerNetwork
Retroperitoneal and Pelvic Myeloid Sarcoma in a Patient With JAK2-Positive Polycythemia Vera: A Case Report - Cureus
Jakafi XR Approved for Myelofibrosis, Polycythemia Vera, and GVHD - Hematology Advisor
Breaking Down the Standard of Care for Patients With Polycythemia Vera - Cure Today
Sequential Transformation of Polycythemia Vera to Myelofibrosis and KMT2A-Rearranged Acute Myeloid Leukemia Treated With Revumenib: A Rare Case of Clonal Evolution - Cureus
JAK Inhibitors Expand Treatment Options in Polycythemia Vera and Myelofibrosis - OncLive
SANRECO Trial Explores Divesiran for Polycythemia Vera Treatment - Cure Today
Low neutrophil-to-lymphocyte ratio identifies secondary polycythemia in patients with erythrocytosis - Nature
GLP-1 Therapy Linked to Improved Outcomes in Polycythemia Vera - Cure Today
FDA Approves Ruxolitinib Extended-Release Tablets for Myelofibrosis, Polycythemia Vera, and GVHD - Docwire News
Aaron Gerds, MD, on Using an AI System to Identify Patients Eligible for a Polycythemia Vera Trial - The ASCO Post
FDA Clears Once-Daily Ruxolitinib Tablets for Myelofibrosis, Polycythemia Vera, and GVHD - OncLive
Weekly injection a potential new treatment option for polycythemia vera - Wiley
Key Link Found in Ropeginterferon Treatment for Polycythemia Vera - Docwire News
FDA Application Submitted for Rusfertide Treatment in Polycythemia Vera - Cure Today
GLP-1 Agonists Show Therapeutic Benefits in Polycythemia Vera Population - CancerNetwork
FDA Grants Priority Review to Rusfertide in Polycythemia Vera - OncLive
FDA Grants Breakthrough Therapy Designation to Rusfertide for Erythrocytosis in Polycythemia Vera - OncLive
NDA Submitted to FDA for Rusfertide for Polycythemia Vera - OncLive
FDA Accepts New Drug Application for Rusfertide, Grants Priority Review In Polycythemia Vera - HCPLive
ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap - Fierce Biotech
Treating Low-Risk Polycythemia Vera in the Second Line - Targeted Oncology
AI Screening Platform Accelerates Trial Recruitment in Polycythemia Vera - Cleveland Clinic
Weight-Loss Drugs for Polycythemia Vera? - Medscape
Deciphera Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 INTREPID Study of Sapablursen in Polycythemia Vera - BioSpace
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera - PR Newswire
FDA Grants Orphan Status to Novel JAK2 Inhibitor for Polycythemia Vera - Targeted Oncology
Rampal Analyzes Ropeginterferon Data in Low-Risk Polycythemia Vera - Targeted Oncology
suppression and event-free survival in polycythemia vera - Nature
Novartis Korea's Jakavi wins reimbursement for 2nd-line treatment of polycythemia vera - koreabiomed.com
Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population‐Based Study on Treatment Patterns, Vascular Complications and Survival - Larsson - 2026 - European Journal of Haematology - Wiley Online Library
Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera - CancerNetwork
Dr Jain on Persisting Gaps in Defining Disease Modification in Polycythemia Vera and Myelofibrosis - OncLive
Considerations for Selection and Sequencing in Polycythemia Vera and Myelofibrosis - OncLive
Rusfertide Approval Would Move Past ‘Archaic’ Polycythemia Vera Standard - CancerNetwork
Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities - Wiley Online Library
Dr Jain on the Role of Ruxolitinib in Polycythemia Vera and Myelofibrosis - OncLive
Does Ono’s Phase 3 Sapablursen Trial in Polycythemia Vera Reshape The Bull Case For Ono Pharmaceutical (TSE:4528)? - simplywall.st
Divesiran Shows Promise as RNA-Based Approach in Polycythemia Vera - OncLive
Cardioembolic ST-Elevation Myocardial Infarction in a Patient With Atrial Fibrillation and Polycythemia Vera - Cureus
Rusfertide Earns Breakthrough Therapy Designation in Polycythemia Vera - Cure Today
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - BioSpace
The use of ropeginterferon alpha-2b in the treatment of polycythemia vera in a young patient with joint pain - Via Medica Journals
Dr Kremyanskaya on the Ongoing Development of Divesiran for Polycythemia Vera - OncLive
JAK2 Unmutated Erythrocytosis: 2026 Update on Diagnosis and Management - Wiley Online Library
Takeda and Protagonist Announce Submission of Rusfertide NDA for Polycythemia Vera - HCPLive
Polycythemia vera: Phlebotomy remains high-burden and often insufficient in real-world care - Vera Health
New Therapies Advance for Rare Blood Cancer Polycythemia Vera - Cure Today
Oncology Drugs Fast-Tracked and Prioritized by the FDA in March 2026 - Oncology News Central
When Rusfertide May Become Accessible for Those with Polycythemia Vera - Cure Today
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease - Yahoo Finance
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera - Business Wire
Dr. Roach: Symptoms, not numbers, are the main drivers for a phlebotomy - The Detroit News
Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera - PR Newswire
New Drug Application Approved for Rusfertide for Adults with Polycythemia Vera - Onco'Zine
Polycythemia vera: High-dose rapid titration of ropeginterferon speeds early responses - Vera Health
Rusfertide Shows Promising Efficacy and Safety in Treating Polycythemia Vera - Hematology Advisor
Takeda And Protagonist Secure FDA Priority Review For Rusfertide In Polycythemia Vera - BioPharma APAC
Rusfertide Shows Promise in Treating Polycythemia Vera - Hematology Advisor
Synchronous Primary Hyperparathyroidism and Polycythemia Vera: A Case Report and Literature Review - Wiley Online Library
Erythrocytosis and thromboembolic risks associated with SGLT2 inhibitors in type 2 diabetes | Scientific Reports - Nature
Rusfertide Poised to Transform Polycythemia Vera Care: Andrew Kuykendall, MD - AJMC
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting - Business Wire
Rusfertide Gains Breakthrough Therapy Designation for Polycythemia Vera - Pharmacy Times
Polycythemia vera and essential thrombocythemia: Identify patients at highest risk for fibrotic progression - Vera Health
Different Colours of Polycythemia Vera: A Case Series - Cureus
What Blood Cancer Does Anna Have On General Hospital? Her Polycythemia Vera Diagnosis Explained - Soap Opera Digest
When the Air Gets Thin, and the Blood Gets Thick: Choroidal Hemangioma in High-Altitude Polycythemia - Cureus
Dr Gangat on Reducing JAK2 Allele Burden With Ruxolitinib or Ropeginterferon Alfa-2b in Polycythemia Vera - OncLive
Characteristics and Outcomes of IgA Nephropathy Patients With SGLT2 Inhibitor-Induced Polycythemia - Cureus
Shining Light on How Protagonist, Takeda Drug Brings Treatment of a Rare Blood Disease Out of the Dark Ages - MedCity News
Besremi gains reimbursement as second-line therapy for polycythemia vera in Korea - koreabiomed.com
ASH 2025: Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera - Onco'Zine
Rusfertide Cuts Number of Needed Blood Draws to Treat PCV - National Cancer Institute (.gov)
The Hemojuvelin-Hepcidin Axis as a Target for the Treatment of Anemia or Conversely Polycythemia - Wiley Online Library
A molecular signature predicts hematologic evolution in polycythemia vera patients | Leukemia - Nature
Foreign Language Equivalents
Foreign Language Equivalents of 'polycythemia'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
polyctthemia,   polycuthemia,   olycythemia,   pokycythemia,   polycyyhemia,   poolycythemia,   polycythema,   polycytthemia,   plycythemia,   pilycythemia,   polycyythemia,   pplycythemia,   [olycythemia,   polycythemua,   ppolycythemia,   polcyythemia,   oplycythemia,   polyxythemia,   polcythemia,   polycytgemia,   polycyhtemia,   polycythmeia,   polycytheima,   polycythhemia,   polycythemiaa,   polycytehmia,   polyythemia,   polycyhemia,   polycthemia,   pollycythemia,   polycythenia,   polycytjemia,   po;ycythemia,   polyvythemia,   polucythemia,   polycythrmia,   ploycythemia,   poylcythemia,   oolycythemia,   polycythemai,   polyycthemia,   polycythemis,   polyycythemia,   polyccythemia,   polycythemoa,   polycytemia,   polycytheia,   polycythwmia,   poycythemia,   polyctyhemia,   polycythemiia,   polycytheemia,   polycythmia,   polycythemmia,   polycythemi,   polycyrhemia,   poltcythemia,   polycythe,ia
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z